Insider Selling: LeMaitre Vascular (NASDAQ:LMAT) Director Sells $903,955.20 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director David Roberts sold 8,464 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the transaction, the director directly owned 17,979 shares in the company, valued at $1,920,157.20. This represents a 32.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

LeMaitre Vascular Stock Performance

LMAT opened at $106.41 on Thursday. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The firm has a market cap of $2.42 billion, a PE ratio of 42.39, a P/E/G ratio of 3.11 and a beta of 0.66. The business has a fifty day simple moving average of $88.39 and a 200-day simple moving average of $88.60. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The business had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. During the same period in the prior year, the business posted $0.49 earnings per share. LeMaitre Vascular’s revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be given a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend is Thursday, March 12th. LeMaitre Vascular’s payout ratio is 31.87%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Wells Fargo & Company raised their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, February 24th. Finally, Barrington Research increased their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Hold” and an average price target of $105.80.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Royal Bank of Canada lifted its holdings in shares of LeMaitre Vascular by 1.5% during the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after buying an additional 1,735 shares during the last quarter. AQR Capital Management LLC increased its holdings in LeMaitre Vascular by 36.4% in the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock worth $2,339,000 after buying an additional 7,445 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in LeMaitre Vascular by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after acquiring an additional 539 shares in the last quarter. Millennium Management LLC lifted its stake in LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after acquiring an additional 115,141 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after acquiring an additional 55,804 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.